Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated May 05, 2025, titled "Press release ".
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Onesource Specialty Pharma reported strong Q4 and FY25 results in its first year post-listing. Q4FY25 revenue rose 22% YoY to ₹4,260 million, with EBITDA up 79% to ₹1,825 million and EBITDA margin expanding sharply by 1,362 basis points to 43%. PAT swung from a loss of ₹112 million in Q4FY24 to a profit of ₹992 million. For the full year FY25, revenue grew 30% to ₹14,449 million and EBITDA more than doubled (+104%) to ₹4,665 million with margins at 32%. Adjusted FY25 PAT stood at ₹9,361 million and adjusted EPS at ₹21.42, benefiting from growth in Drug-Device Combinations and Biologics, along with integration synergies from acquired entities. The company also won 39 new RFPs/licensing deals during the year.
This is a strong earnings beat with broad-based growth across revenue, EBITDA, and profitability in the company's debut listed year, likely to be viewed positively by the market and supportive of the stock price. The margin expansion and return to profit suggest the business is gaining operational leverage, though FY25 PAT is flattered by exceptional/adjustment items and investors should watch the underlying run-rate.